Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

NCT00864253 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00864253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00864253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
April 23, 2009
Completion date
February 12, 2014
Enrollment
529 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma